These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38868885)

  • 1. Identification of Potential Biomarkers of EGFR Mutation in Pleural Effusion of Non-Small Cell Lung Cancer Patients Based on Metabolomics.
    Yu J; Xu H; Feng T; Xie T; Shi T
    Clin Lab; 2024 Jun; 70(6):. PubMed ID: 38868885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.
    Liu X; Lu Y; Zhu G; Lei Y; Zheng L; Qin H; Tang C; Ellison G; McCormack R; Ji Q
    J Clin Pathol; 2013 Dec; 66(12):1065-9. PubMed ID: 23888061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
    Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of malignant pleural effusion.
    Wang K; Hu X; Chen Y; Yi X; Han X; Zhu D; Zhu B; Luo H
    Clin Respir J; 2024 Jan; 18(1):e13705. PubMed ID: 37775991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
    Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
    Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
    Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
    Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
    Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
    Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer.
    Lin R; Li Y; Lin Y; Tian W; Jiang L; Li J
    Diagn Cytopathol; 2023 Jul; 51(7):397-405. PubMed ID: 37078537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.
    Wang S; Chen H; Zhong J; Qin H; Bai H; Zhao J; Wang J
    Lung Cancer; 2019 Sep; 135():116-122. PubMed ID: 31446983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay.
    Wang MC; Wang CL; Chen TL; Chang JW; Lu JJ; Chang PY; Chiou CC
    Clin Chem Lab Med; 2017 Oct; 55(12):1979-1986. PubMed ID: 28787267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma.
    Liu D; Lu Y; Hu Z; Wu N; Nie X; Xia Y; Han Y; Li Q; Zhu G; Bai C
    PLoS One; 2014; 9(2):e89946. PubMed ID: 24587142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of exon 20 S768I EGFR mutation detected in malignant pleural effusions: A poor prognosticator of NSCLC.
    D'Souza G; Dhar C; Kyalanoor V; Yadav L; Sharma M; Nawaz S M; Srivastava S
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1262. PubMed ID: 32761886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth factor receptor (EGFR) mutation status of malignant pleural effusion.
    Wang L; Guo T; Lu Q; Yan X; Zhong D; Zhang Z; Ni Y; Han Y; Cui D; Li X; Huang L
    ACS Appl Mater Interfaces; 2015 Jan; 7(1):359-69. PubMed ID: 25495142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
    Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
    Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
    Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
    Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation.
    Zou J; Bella AE; Chen Z; Han X; Su C; Lei Y; Luo H
    J Int Med Res; 2014 Oct; 42(5):1110-7. PubMed ID: 25239875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
    Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
    Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.